Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone (+P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC).

Anuradha Jayaram,Anna Wingate,Mansour Taghavi Azar Sharabiani,Daniel Wetterskog,Fabio Calabrò,Lorraine Barwell,Weibke Arlt,Axel S. Merseburger,Susan Feyerabend,Alfredo Berruti,Florence Lefresne,Dong Shen,Michael Gormley,Gurpreet Kapoor,Weimin Li,Robert Jones,Cora N. Sternberg,Bertrand F. Tombal,Gerhardt Attard

Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone (+P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC).

2018

Anuradha Jayaram
Anna Wingate
Mansour Taghavi Azar Sharabiani
Daniel Wetterskog
Fabio Calabrò
Lorraine Barwell
Weibke Arlt
Axel S. Merseburger
Susan Feyerabend
Alfredo Berruti
Florence Lefresne
Dong Shen
Michael Gormley
Gurpreet Kapoor
Weimin Li
Robert Jones
Cora N. Sternberg
Bertrand F. Tombal
Gerhardt Attard

5067Background: pAR gene aberrations in mCRPC patients (pts) may be associated with worse outcome on AA+P/D. Methods: This was an international, multi-institutional, open-label phase 2 study of AA ...

Keywords:

Abiraterone acetate
Dexamethasone
Androgen receptor
Prostate cancer
Physical therapy
Prednisone
Castration
Endocrinology
Internal medicine
Medicine
Phases of clinical research
Oncology
castration resistant
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations